Table 3.

Phase III randomized trials of first‐line EGFR TKI versus platinum doublet chemotherapy in patients with EGFR mutant non‐small cell lung cancer

First author	Study	TKI	# Pts	ORR %	Median PFS (mo)	Median OS (mo)
Mok [118]	IPASS	Gefitinib	261	71 vs 47	9.8 vs 6.4	21.6 vs. 21.9
Maemondo [119] Inoue [120]	NEJGSG002	Gefitinib	228	73 vs 31	10.8 vs 5.4	27.7 vs 26.6
Mitsudomi [121] Yoshioka [122]	WJTOG3405	Gefitinib	177	62 vs 32	9.2 vs 6.3	34.9 vs 37.3
Zhou [123] Zhou [124]	Optimal	Erlotinib	154	83 vs 36	13.1 vs 4.6	22.6 vs. 28.8
Han [125]	First Signal	Gefitinib	309	55 vs 46	5.8 vs 6.4	22.3 vs 22.9
Rosell [126]	EURTAC	Erlotinib	154	58 vs 15	9.7 vs 5.2	19.3 vs. 19.5
Sequist [127] Yang [128]	LUX‐Lung 3	Afatinib	345	56 vs 23	11.1 vs 6.9	28.2 vs 28.2
Wu [129]	LUX‐Lung 6	Afatinib	364	67 vs 23	11.0 vs 5.6	23.6 vs 23.5

Abbreviations: EGFR, epidermal growth factor receptor; EURTAC, European randomized trial of tarceva versus chemotherapy; First Signal, first‐line single‐agent iressa versus gemcitabine and cisplatin trial in never‐smokers with adenocarcinoma of the lung; IPASS, Iressa Pan‐Asia study; LUX‐Lung 3, phase III trial of afatinib vs. pemetrexed/cisplatin in locally advanced or metastatic patients; LUX‐Lung 6, equivalent to LUX‐Lung 3 but with gemcitabine/cisplatin chemotherapy; NEJGSG002, North East Japan Gefitinib Study Group 002 trial; Optimal, erlotinib versus standard chemotherapy in the first‐line treatment of patients with advanced EGFR mutation–positive non‐small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; TKI, tyrosine kinase inhibitor; WJTOG, West Japan Thoracic Oncology Group.